You can buy or sell TARS and other stocks, options, and ETFs commission-free!
Tarsus Pharmaceuticals, Inc. develops and manufactures drug treatments for Blepharitis. The company focuses on treatment of Blepharitis, which is a common ocular condition, characterized by inflammation of the eyelid, which can impact the anterior or posterior lid or both. The company was founded by Bobak Azamian and D. Michael Ackermann in 2017 and is headquartered in Irvine, CA. The listed name for TARS is Tarsus Pharmaceuticals, Inc. Common Stock.
52 Week High
52 Week Low
— per share
Expected Mar 16, Pre-Market